Literature DB >> 29805621

miR-19 in blood plasma reflects lung cancer occurrence but is not specifically associated with radon exposure.

Olga Bulgakova1, Dinara Zhabayeva1, Assiya Kussainova1, Alessandra Pulliero2, Alberto Izzotti2, Rakhmetkazhi Bersimbaev1.   

Abstract

Radon is one of the most powerful carcinogens, particularly in terms of lung cancer onset and development. miRNAs may be considered not only as markers of the ongoing tumorigenesis but also as a hallmark of exposure to radiation, including radon and its progeny. Therefore, the purpose of the present study was to estimate the value of plasma miR-19b-3p level as the prospective marker of the response to radon exposure in lung cancer pathogenesis. A total of 136 subjects were examined, including 49 radon-exposed patients with lung cancer, 37 patients with lung cancer without radon exposure and 50 age/sex matched healthy controls. Total RNA from blood samples was extracted and used to detect miR-19b-3p expression via reverse transcription quantitative-polymerase chain reaction. The 2-ΔΔCq method was used to quantify the amount of relative miRNA. The plasma level of p53 protein was determined using a Human p53 ELISA kit. Plasma miR-19b-3p level was significantly higher in the patients with lung cancer groups, compared with the healthy control group (P<0.0001). No other statistically significant differences were determined in the expression level of plasma miR-19b-3p between patients diagnosed with lung cancer exposed to radon and not exposed to radon. The expression level of free circulating miR-19b-3p was higher in the group of non-smoking patients with lung cancer, compared with smokers with lung cancer. The miR-19b-3p was 1.4-fold higher in non-smokers than in smokers (P<0.05). No association between plasma levels of p53 protein and miR-19b-3p freely circulating in patients with lung cancer was observed. No other statistically significant differences were determined in the plasma p53 protein level between patients diagnosed with lung cancer exposed and not exposed to radon. These results indicated that detection of miR-19b-3p levels in plasma potentially could be exploited as a noninvasive method for the lung cancer diagnostics. However, this miRNA is not suitable as the precise marker for radon impact.

Entities:  

Keywords:  biomarker; lung cancer; miRNA; p53; radon

Year:  2018        PMID: 29805621      PMCID: PMC5950512          DOI: 10.3892/ol.2018.8392

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  62 in total

Review 1.  MicroRNAs: small RNAs with big effects.

Authors:  Dany Anglicheau; Thangamani Muthukumar; Manikkam Suthanthiran
Journal:  Transplantation       Date:  2010-07-27       Impact factor: 4.939

2.  Gene expression profiles of small-cell lung cancers: molecular signatures of lung cancer.

Authors:  Masaya Taniwaki; Yataro Daigo; Nobuhisa Ishikawa; Atsushi Takano; Tatsuhiko Tsunoda; Wataru Yasui; Kouki Inai; Nobuoki Kohno; Yusuke Nakamura
Journal:  Int J Oncol       Date:  2006-09       Impact factor: 5.650

Review 3.  MicroRNAs as biomarkers for early breast cancer diagnosis, prognosis and therapy prediction.

Authors:  Farah J Nassar; Rihab Nasr; Rabih Talhouk
Journal:  Pharmacol Ther       Date:  2016-12-01       Impact factor: 12.310

4.  Mutations of p53 and ras genes in radon-associated lung cancer from uranium miners.

Authors:  K H Vähäkangas; J M Samet; R A Metcalf; J A Welsh; W P Bennett; D P Lane; C C Harris
Journal:  Lancet       Date:  1992-03-07       Impact factor: 79.321

Review 5.  Employment opportunities for non-coding RNAs.

Authors:  Céline Morey; Philip Avner
Journal:  FEBS Lett       Date:  2004-06-01       Impact factor: 4.124

6.  Epidemiologic characteristics of compensated occupational lung cancers among Korean workers.

Authors:  Yeon-Soon Ahn; Kyoung Sook Jeong
Journal:  J Korean Med Sci       Date:  2014-11-04       Impact factor: 2.153

Review 7.  Major Tumor Suppressor and Oncogenic Non-Coding RNAs: Clinical Relevance in Lung Cancer.

Authors:  Kentaro Inamura
Journal:  Cells       Date:  2017-05-09       Impact factor: 6.600

8.  A six-microRNA panel in plasma was identified as a potential biomarker for lung adenocarcinoma diagnosis.

Authors:  Xin Zhou; Wei Wen; Xia Shan; Wei Zhu; Jing Xu; Renhua Guo; Wenfang Cheng; Fang Wang; Lian-Wen Qi; Yan Chen; Zebo Huang; Tongshan Wang; Danxia Zhu; Ping Liu; Yongqian Shu
Journal:  Oncotarget       Date:  2017-01-24

9.  miR-17-92a-1 cluster host gene (MIR17HG) evaluation and response to neoadjuvant chemoradiotherapy in rectal cancer.

Authors:  Chiara Molinari; Samanta Salvi; Flavia Foca; Nazario Teodorani; Luca Saragoni; Maurizio Puccetti; Alessandro Passardi; Stefano Tamberi; Andrea Avanzolini; Enrico Lucci; Daniele Calistri
Journal:  Onco Targets Ther       Date:  2016-05-06       Impact factor: 4.147

10.  Radon Exposure Assessment and Relative Effective Dose Estimation to Inhabitants of Puglia Region, South Italy.

Authors:  Maria Quarto; Mariagabriella Pugliese; Giuseppe La Verde; Filomena Loffredo; Vincenzo Roca
Journal:  Int J Environ Res Public Health       Date:  2015-11-23       Impact factor: 3.390

View more
  10 in total

1.  MicroRNA profiling in BEAS-2B cells exposed to alpha radiation reveals potential biomarkers for malignant cellular transformation.

Authors:  Xuhong Dang; Haipeng Lin; Youchen Li; Xiuli Guo; Yayi Yuan; Ruifeng Zhang; Xiaozhen Li; Dongliang Chai; Yahui Zuo
Journal:  Toxicol Res (Camb)       Date:  2020-12-12       Impact factor: 3.524

2.  Clinical Significance and Biological Function of miR-1274a in Non-small Cell Lung Cancer.

Authors:  Shi-Jia Zhu; Xiao Wang; Song-Liu Hu; Yu Fang; Bi-Xi Guan; Jian Li; Gen Li; Jian-Yu Xu
Journal:  Mol Biotechnol       Date:  2021-08-24       Impact factor: 2.695

3.  MALAT1 affects hypoxia-induced vascular endothelial cell injury and autophagy by regulating miR-19b-3p/HIF-1α axis.

Authors:  Huzi Liu; Chunli Shi; Yongzhi Deng
Journal:  Mol Cell Biochem       Date:  2020-01-13       Impact factor: 3.842

4.  MiR-19b-3p promotes tumor progression of non-small cell lung cancer via downregulating HOXA9 and predicts poor prognosis in patients.

Authors:  Zu-Lei Li; Dong Li; Guo-Qiang Yin
Journal:  Histol Histopathol       Date:  2022-03-11       Impact factor: 2.130

5.  Circular RNA SMARCA5 inhibits the proliferation, migration, and invasion of non-small cell lung cancer by miR-19b-3p/HOXA9 axis.

Authors:  Yaqiu Wang; Huiping Li; Hong Lu; Yaguang Qin
Journal:  Onco Targets Ther       Date:  2019-08-30       Impact factor: 4.147

6.  Upregulation of microRNA-181a-5p increases the sensitivity of HS578T breast cancer cells to cisplatin by inducing vitamin D receptor-mediated cell autophagy.

Authors:  Jianmin Lin; Xuming Chen; Mingliang Sun; Xiaojiao Qu; Ye Wang; Chenxi Li; Xiujuan Li; Li Zhao; Zhiying Su; Huiming Ye
Journal:  Oncol Lett       Date:  2021-02-03       Impact factor: 2.967

Review 7.  Role of microRNAs in Lung Carcinogenesis Induced by Asbestos.

Authors:  Rakhmetkazhy Bersimbaev; Olga Bulgakova; Akmaral Aripova; Assiya Kussainova; Oralbek Ilderbayev
Journal:  J Pers Med       Date:  2021-02-03

8.  Far upstream element -binding protein 1 (FUBP1) participates in the malignant process and glycolysis of colon cancer cells by combining with c-Myc.

Authors:  Shanwei Wang; Yanli Wang; Sheng Li; Shen Nian; Wenjing Xu; Fenli Liang
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

9.  Contributions of Circulating microRNAs for Early Detection of Lung Cancer.

Authors:  Jody Vykoukal; Johannes F Fahrmann; Nikul Patel; Masayoshi Shimizu; Edwin J Ostrin; Jennifer B Dennison; Cristina Ivan; Gary E Goodman; Mark D Thornquist; Matt J Barnett; Ziding Feng; George A Calin; Samir M Hanash
Journal:  Cancers (Basel)       Date:  2022-08-30       Impact factor: 6.575

Review 10.  Radon Biomonitoring and microRNA in Lung Cancer.

Authors:  Rakhmet Bersimbaev; Alessandra Pulliero; Olga Bulgakova; Kussainova Asia; Akmara Aripova; Alberto Izzotti
Journal:  Int J Mol Sci       Date:  2020-03-20       Impact factor: 5.923

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.